Raymond James Starts Sage Therapeutics (SAGE) at Outperform
- Wall St stumbles as FBI to review more Clinton emails
- FBI to review more emails related to Clinton's private email use
- Unusual 11 Mid-Day Movers 10/28: (GRVY) (VRTS) (ITGR) Higher; (OPXA) (SNMX) (STON) Lower
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Raymond James initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with an Outperform rating and a price target of $75.00.
Shares of Sage Therapeutics closed at $40.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Maxim Group Starts Vuzix Corp. (VUZI) at Buy
- Needham & Company Starts AMAG Pharmaceuticals (AMAG) at Buy
- UPDATE: Chardan Capital Markets Starts Clovis Oncology (CLVS) at 'Sell' With Price Target of $15
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Related EntitiesRaymond James
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!